CU20180011A7 - Composiciones farmacéuticas que comprenden compuestos derivados de diaminopirido (3,2-d) como moduladores de receptor de tipo toll - Google Patents

Composiciones farmacéuticas que comprenden compuestos derivados de diaminopirido (3,2-d) como moduladores de receptor de tipo toll

Info

Publication number
CU20180011A7
CU20180011A7 CUP2018000011A CU20180011A CU20180011A7 CU 20180011 A7 CU20180011 A7 CU 20180011A7 CU P2018000011 A CUP2018000011 A CU P2018000011A CU 20180011 A CU20180011 A CU 20180011A CU 20180011 A7 CU20180011 A7 CU 20180011A7
Authority
CU
Cuba
Prior art keywords
pharmaceutical compositions
compounds derived
diaminopired
include compounds
type receiver
Prior art date
Application number
CUP2018000011A
Other languages
English (en)
Inventor
Evangelos Aktoudianakis
Gregory Chin
Richard L Mackman
Samuel E Metobo
Michael R Mish
Hyung-Jung Pyun
Jeff Zablocki
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CU20180011A7 publication Critical patent/CU20180011A7/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La presente solicitud se refiere en general a composiciones farmacéuticas que comprenden compuestos derivados de diaminopirido[3,2 D]pirimidina, los cuales presentan la fórmula </p> <p>ESPACIO PARA FÓRMULA (I)</p> <p>que son útiles en Ia modulación de los receptores tipo Toll, como por ejemplo TLR-8, en enfermedades causadas por virus  como el VHB, VHC, y VIH, o como el cáncer.</p>
CUP2018000011A 2015-03-04 2016-03-02 Composiciones farmacéuticas que comprenden compuestos derivados de diaminopirido (3,2-d) como moduladores de receptor de tipo toll CU20180011A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562128397P 2015-03-04 2015-03-04
US201562250403P 2015-11-03 2015-11-03
PCT/US2016/020499 WO2016141092A1 (en) 2015-03-04 2016-03-02 Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds

Publications (1)

Publication Number Publication Date
CU20180011A7 true CU20180011A7 (es) 2018-06-05

Family

ID=55590135

Family Applications (2)

Application Number Title Priority Date Filing Date
CUP2018000011A CU20180011A7 (es) 2015-03-04 2016-03-02 Composiciones farmacéuticas que comprenden compuestos derivados de diaminopirido (3,2-d) como moduladores de receptor de tipo toll
CUP2017000115A CU20170115A7 (es) 2015-03-04 2016-03-02 Compuestos moduladores de receptor de tipo toll

Family Applications After (1)

Application Number Title Priority Date Filing Date
CUP2017000115A CU20170115A7 (es) 2015-03-04 2016-03-02 Compuestos moduladores de receptor de tipo toll

Country Status (42)

Country Link
US (4) US9670205B2 (es)
EP (3) EP3097102B1 (es)
JP (4) JP6182278B2 (es)
KR (3) KR102394917B1 (es)
CN (2) CN112174960B (es)
AU (4) AU2016216673B2 (es)
BR (1) BR102016004764B1 (es)
CA (1) CA2978188C (es)
CL (1) CL2017002225A1 (es)
CO (1) CO2017009032A2 (es)
CR (1) CR20170395A (es)
CU (2) CU20180011A7 (es)
CY (2) CY1120143T1 (es)
DK (2) DK3097102T3 (es)
DO (1) DOP2017000203A (es)
EA (1) EA035093B1 (es)
EC (1) ECSP17058129A (es)
ES (2) ES2656225T3 (es)
HK (2) HK1226062B (es)
HR (2) HRP20172003T1 (es)
HU (2) HUE038059T2 (es)
IL (1) IL254164B (es)
LT (2) LT3321265T (es)
MA (2) MA39601A (es)
MD (2) MD20170081A2 (es)
ME (1) ME02893B (es)
MX (2) MX2017011307A (es)
NZ (1) NZ735176A (es)
PE (1) PE20180031A1 (es)
PH (1) PH12017501590A1 (es)
PL (2) PL3097102T3 (es)
PT (2) PT3097102T (es)
RS (1) RS56787B1 (es)
SA (1) SA517382248B1 (es)
SG (1) SG11201606876RA (es)
SI (2) SI3321265T1 (es)
SV (1) SV2017005528A (es)
TW (1) TWI705964B (es)
UA (1) UA123090C2 (es)
UY (1) UY36577A (es)
WO (1) WO2016141092A1 (es)
ZA (2) ZA201705958B (es)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031737B1 (ru) 2010-06-03 2019-02-28 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы
WO2014018567A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
EP3097102B1 (en) 2015-03-04 2017-10-18 Gilead Sciences, Inc. Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
EP3349757A1 (en) * 2015-09-15 2018-07-25 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
AR106991A1 (es) 2015-12-15 2018-03-07 Gilead Sciences Inc Anticuerpos neutralizantes del virus de inmunodeficiencia humana
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
EP3507276B1 (en) 2016-09-02 2021-11-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
AU2017332771A1 (en) * 2016-09-23 2019-04-04 Abbvie Inc. Dose adjustment
EP3515911A1 (en) * 2016-09-23 2019-07-31 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
KR102305215B1 (ko) 2016-10-14 2021-09-28 프리시젼 바이오사이언시스 인코포레이티드 B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
RU2650610C1 (ru) * 2017-02-28 2018-04-16 Васильевич Иващенко Александр Противовирусная композиция и способ ее применения
KR101899773B1 (ko) 2017-03-07 2018-09-18 일동제약(주) 베시포비르 디피복실 또는 이의 약제학적 허용되는 염 함유 과립, 상기 과립을 포함하는 약제학적 조성물 및 이의 제조 방법
JOP20180040A1 (ar) * 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
WO2018233648A1 (zh) * 2017-06-21 2018-12-27 南京明德新药研发股份有限公司 作为TLR8激动剂的异噻唑并[4,3-d]嘧啶-5,7-二胺衍生物
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
CN111051305A (zh) 2017-08-22 2020-04-21 吉利德科学公司 治疗性杂环化合物
CN111065636B (zh) * 2017-09-22 2022-08-23 江苏恒瑞医药股份有限公司 稠合杂芳基衍生物、其制备方法及其在医药上的应用
CN108069963B (zh) * 2017-11-17 2020-01-14 清华大学 吡啶并嘧啶衍生物或其盐及其制法、药物组合物和用途
KR102248165B1 (ko) 2017-12-07 2021-05-06 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
EP3724222A1 (en) 2017-12-15 2020-10-21 Silverback Therapeutics, Inc. Antibody construct-drug conjugate for the treatment of hepatitis
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
JP7037667B2 (ja) 2017-12-20 2022-03-16 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. Stingアダプタータンパク質を活性化するホスホン酸結合を有する3’3’環状ジヌクレオチド
CN111836805B (zh) 2018-02-15 2023-07-14 吉利德科学公司 吡啶衍生物及其用于治疗hiv感染的用途
KR20230145536A (ko) 2018-02-16 2023-10-17 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 2,4-二胺基喹唑啉衍生物及其醫學用途
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
KR20210028208A (ko) * 2018-07-03 2021-03-11 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피리도피리미딘 유도체, 그의 제조 방법 및 그의 의약 용도
CN118063599A (zh) 2018-07-03 2024-05-24 吉利德科学公司 靶向hiv gp120的抗体和使用方法
EP3818052A1 (en) 2018-07-06 2021-05-12 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
CN112384283B (zh) 2018-07-06 2023-08-15 吉利德科学公司 治疗性的杂环化合物
CA3216031A1 (en) 2018-07-16 2020-01-23 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
WO2020029968A1 (zh) * 2018-08-07 2020-02-13 中国科学院生物物理研究所 活化cd4+t细胞的方法
US20210323977A1 (en) * 2018-08-28 2021-10-21 Hoffmann-La Roche Inc. Pyrrolidinyl amide compounds for the treatment of autoimmune disease
CN115650979A (zh) * 2018-09-19 2023-01-31 正大天晴药业集团股份有限公司 Tlr8激动剂
US11179397B2 (en) 2018-10-03 2021-11-23 Gilead Sciences, Inc. Imidazopyrimidine derivatives
EP3875451B1 (en) * 2018-10-19 2024-01-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tlr8 agonist
LT3873903T (lt) 2018-10-31 2024-05-10 Gilead Sciences, Inc. Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
CN109336740B (zh) * 2018-11-27 2021-08-17 湖南有色郴州氟化学有限公司 一种4,4,4-三氟-1-丁醇的制备方法
JP7287708B2 (ja) 2019-02-08 2023-06-06 プロジェニア インコーポレイテッド Toll-like受容体7または8アゴニストとコレステロールの結合体およびその用途
WO2020176510A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
WO2020176505A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
AU2020231115A1 (en) 2019-03-07 2021-08-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) * 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2020239855A1 (en) 2019-05-29 2020-12-03 Syngenta Crop Protection Ag Microbiocidal derivatives
CA3140707A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
CA3140708A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
MA56502A (fr) * 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Co Promédicaments à base de quinazoline pour le traitement d'infections virales et d'autres maladies
CN114341185A (zh) 2019-06-19 2022-04-12 希沃尔拜克治疗公司 抗间皮素抗体及其免疫缀合物
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CN112174903B (zh) 2019-07-01 2022-07-12 清华大学 Tlr8的小分子调节剂
CA3147836A1 (en) * 2019-08-19 2021-02-25 Shanghai Zhimeng Biopharma, Inc. 2-aminopyrimidine compounds and pharmaceutical compositions and uses thereof
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
KR20220074917A (ko) 2019-09-30 2022-06-03 길리애드 사이언시즈, 인코포레이티드 Hbv 백신 및 hbv를 치료하는 방법
KR20220106165A (ko) 2019-11-26 2022-07-28 길리애드 사이언시즈, 인코포레이티드 Hiv의 예방을 위한 캡시드 억제제
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
CN114828852A (zh) 2019-12-24 2022-07-29 豪夫迈·罗氏有限公司 用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合
JP2023509175A (ja) 2020-01-02 2023-03-07 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 ピリドピリミジン系誘導体の結晶形及びその調製方法
WO2021177679A1 (ko) 2020-03-02 2021-09-10 성균관대학교산학협력단 병원균 외벽 성분 기반 생병원체 모방 나노 입자 및 그 제조 방법
WO2021185312A1 (zh) * 2020-03-18 2021-09-23 正大天晴药业集团股份有限公司 一种tlr8激动剂晶型
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ, インコーポレイテッド 4’-c-置換-2-ハロ-2’-デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
CA3181690A1 (en) 2020-06-25 2021-12-30 Chienhung CHOU Capsid inhibitors for the treatment of hiv
CN115362155B (zh) * 2020-07-22 2024-06-18 中国医药研究开发中心有限公司 芳胺类衍生物及其制备方法和医药用途
EP4194010A1 (en) 2020-08-04 2023-06-14 Progeneer Inc. Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
JP2023536945A (ja) 2020-08-04 2023-08-30 プロジェニア インコーポレイテッド 動力学的に作用するアジュバントアンサンブル
EP4194006A1 (en) 2020-08-04 2023-06-14 Progeneer Inc. Mrna vaccine comprising adjuvant capable of kinetic control
JP2023548310A (ja) 2020-10-30 2023-11-16 アバクタ・ライフ・サイエンシーズ・リミテッド Fap活性化血清半減期延長型治療用コンジュゲート
EP4267559A1 (en) 2020-12-22 2023-11-01 Gilead Sciences, Inc. Substituted indole compounds
CN112763609B (zh) * 2020-12-25 2022-08-26 新疆医科大学第四附属医院 一种针对洋甘菊抗哮喘活性成分筛选提取工艺的研究方法
CN114907337B (zh) * 2021-02-08 2023-06-02 四川大学 靶向cdk4或cdk6的共价抑制剂及其应用
US20240209080A1 (en) 2021-04-10 2024-06-27 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
CN113125602A (zh) * 2021-04-16 2021-07-16 山东铂源药业有限公司 一种哌柏西利中残留溶剂的检测方法
CN117203238A (zh) 2021-04-23 2023-12-08 普方生物制药美国公司 Cd70结合剂、其偶联物及其使用方法
EP4337223A1 (en) 2021-05-13 2024-03-20 Gilead Sciences, Inc. Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
EP4359389A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222439A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
AU2022341114A1 (en) 2021-09-10 2024-02-29 Gilead Sciences, Inc. Thienopyrrole compounds
CN116472047A (zh) * 2021-11-05 2023-07-21 中国医药研究开发中心有限公司 芳胺类衍生物及其制备方法和医药用途
TW202337439A (zh) 2021-12-03 2023-10-01 美商基利科學股份有限公司 用於hiv病毒感染之治療性化合物

Family Cites Families (232)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2512572A (en) 1950-06-20 Substituted pteridines and method
DE267495C (de) 1913-09-07 1913-11-20 Max Schreiber Sicherheitsschloss für schmucksachen
CH231852A (de) 1940-08-09 1944-04-15 Ig Farbenindustrie Ag Verfahren zur Herstellung eines Kondensationsproduktes.
US2581889A (en) 1948-07-07 1952-01-08 Burroughs Wellcome Co Method of preparing pyrimidopyrazines
US2665275A (en) 1948-12-22 1954-01-05 Allen & Hanburys Ltd 2, 4-diamino-7, 8-disubstituted pteridines
GB677342A (en) 1949-08-19 1952-08-13 Ici Ltd New pyrimidine derivatives and their use in the manufacture of pteridin derivatives
US2667486A (en) 1951-05-24 1954-01-26 Research Corp 2,4-diamino pteridine and derivatives
GB763044A (en) 1952-04-18 1956-12-05 Ici Ltd Pteridin derivatives
GB785353A (en) 1953-01-30 1957-10-30 Merck & Co Inc Substituted pteridine derivatives
US2740784A (en) 1954-05-03 1956-04-03 Merck & Co Inc Process for preparing pteridines
US2940972A (en) 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US2939882A (en) 1958-07-21 1960-06-07 Shell Oil Co Stabilized alpha, beta-unsaturated aldehydes
US3081230A (en) 1960-09-08 1963-03-12 Smith Kline French Lab Diuretic and antihypertensive triaminoarylpteridines
US3071587A (en) 1961-07-25 1963-01-01 American Cyanamid Co Cyanoethyl-pteridines
US3159628A (en) 1962-05-28 1964-12-01 Smith Kline French Lab Pteridine-5-oxide derivatives
US3122546A (en) 1962-12-03 1964-02-25 American Home Prod 4, 7-diamino-2-(substituted)-n-substituted-6-pteridinecarboxamides
US3162635A (en) 1962-08-06 1964-12-22 Searle & Co 1, 2, 3, 4-tetrahydro-2, 4-pteridinediones and intermediates
NL131481C (es) 1965-04-15
DE1921308A1 (de) 1969-04-25 1971-01-07 Boehringer Sohn Ingelheim Herzwirksame Zubereitungen
GB1301319A (es) 1970-07-13 1972-12-29
US3859287A (en) 1971-05-05 1975-01-07 Walter Wesley Parish Thiopteridines and process for producing same
US3843791A (en) 1973-01-11 1974-10-22 Pfizer Method of killing insects with quinazolinones and quinazoline-thiones
DE3023369A1 (de) 1980-06-23 1982-01-14 Boehringer Mannheim Gmbh, 6800 Mannheim Aryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0108890B1 (en) 1982-09-20 1988-12-07 The Wellcome Foundation Limited Pharmaceutically active pteridine derivatives
DE3323932A1 (de) 1983-07-02 1985-01-10 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-piperazino-pteridine, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel
DE3445298A1 (de) 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
US5149705A (en) 1987-03-13 1992-09-22 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a tetralin group and having retinoid like activity
IT1204612B (it) 1987-05-14 1989-03-10 Bioresearch Spa Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica
IL88507A (en) 1987-12-03 1993-02-21 Smithkline Beckman Intercredit 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
DE3833393A1 (de) 1988-10-01 1990-04-05 Thomae Gmbh Dr K Verwendung von pteridinen zur verhinderung der primaeren und sekundaeren resistenz bei der chemotherapie und diese verbindungen enthaltende arzneimittel
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
GB8910722D0 (en) 1989-05-10 1989-06-28 Smithkline Beckman Intercredit Compounds
CA2015981A1 (en) * 1989-05-10 1990-11-10 Thomas H. Brown Compounds
GB8912336D0 (en) 1989-05-30 1989-07-12 Smithkline Beckman Intercredit Compounds
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
DE4009941A1 (de) 1990-03-28 1991-10-02 Thomae Gmbh Dr K Verwendung von pteridinen zur sensibilisierung resistenter plasmodien bei der malaria-chemotherapie und diese verbindungen enthaltende arzneimittel
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9125001D0 (en) 1991-11-25 1992-01-22 Ici Plc Heterocyclic compounds
KR100248324B1 (ko) 1992-01-27 2000-04-01 나가야마 오사무 메토트렉세이트 유도체
AU4535893A (en) 1992-06-15 1994-01-04 Regents Of The University Of California, The Screening assay for the identification of immunosuppressive drugs
HU214331B (hu) 1992-06-17 1998-03-02 Gyógyszerkutató Intézet Kft. Eljárás piperazin- és homopiperazinszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
JPH08501564A (ja) 1992-09-22 1996-02-20 セル・セラピューティックス・インコーポレーテッド 新規なエポキシド含有化合物
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5473070A (en) 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
WO1994014065A1 (en) 1992-12-14 1994-06-23 Dana-Farber Cancer Institute, Inc. Methods for identifying and using immunosuppressant compounds
IL108630A0 (en) 1993-02-18 1994-05-30 Fmc Corp Insecticidal substituted 2,4-diaminoquinazolines
US5641783A (en) 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
PH31122A (en) 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
US5281603A (en) 1993-04-23 1994-01-25 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5521190A (en) 1993-05-27 1996-05-28 Fmc Corporation Insecticidal pterdines and 8-deazapteridines
US6043228A (en) 1993-06-08 2000-03-28 Cancer Research Campaign Technology Limited O6 -substituted guanine derivatives, a process for their preparation and their use in treating tumor cells
WO1995013075A1 (en) 1993-11-12 1995-05-18 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
JPH07138238A (ja) 1993-11-16 1995-05-30 Kanebo Ltd 新規キナゾリン誘導体およびそれを有効成分とする抗腫瘍剤
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
DE4418096A1 (de) 1994-05-24 1995-11-30 Cassella Ag Verwendung von Pteridin-Derivaten als Hemmstoffe der NO-Synthase
DE4418097A1 (de) 1994-05-24 1995-11-30 Cassella Ag Verwendung von Tetrahydropteridin-Derivaten als Hemmstoffe der NO-Synthase
US5929046A (en) 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5607936A (en) 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5843943A (en) 1994-12-29 1998-12-01 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
WO1996020710A1 (en) 1994-12-29 1996-07-11 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
AU1301797A (en) 1995-12-22 1997-07-17 Bundesrepublik Deutschland Vertreten Durch Den Bundesminister Fur Gesundheit Polypeptides with interleukin 16 activity, process for the preparation and use thereof
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
US5663335A (en) 1996-03-01 1997-09-02 Pharmagenesis, Inc. Immunosuppressive compounds and methods
AU2666997A (en) 1996-04-15 1997-11-07 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The In vitro prognostic test for progressors and non-progressors after hiv infection
WO1998004558A1 (fr) 1996-07-31 1998-02-05 Artemis, Inc. Piegeurs d'oxygene actifs a base de derives de pterine
KR100650962B1 (ko) 1996-08-30 2007-07-18 다이이치 아스비오파마 가부시키가이샤 질소산화물합성효소(nos)의기능저하에의해유발되는질환의예방또는치료제
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
WO1999050264A1 (fr) 1998-03-30 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Derives de quinazoline
ATE234099T1 (de) 1998-04-24 2003-03-15 Leuven K U Res & Dev Immununterdrückende effekte von 8 substituierten xanthinderivaten
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
JP4315300B2 (ja) * 1998-08-10 2009-08-19 大日本住友製薬株式会社 新規なキナゾリン誘導体
JP4342007B2 (ja) 1998-08-10 2009-10-14 大日本住友製薬株式会社 キナゾリン誘導体
US5992713A (en) 1998-10-23 1999-11-30 Manabat; Gregorio S. Clothes hanger with slidable side attachments
ATE277929T1 (de) 1998-12-28 2004-10-15 4 Aza Bioscience Nv Immunsuppressive wirkungen von pteridinderivaten
US7276506B2 (en) 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US6946465B2 (en) 1999-02-02 2005-09-20 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
WO2000045800A2 (en) 1999-02-02 2000-08-10 K.U. Leuven Research & Development Immunosurpressive effects of pteridine derivatives
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
EE200200140A (et) 1999-09-15 2003-04-15 Warner-Lambert Company Pteridinoonid kui kinaasi inhibiitorid
DE19944767A1 (de) 1999-09-17 2001-03-29 Vasopharm Biotech Gmbh & Co Kg N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
DE10059864A1 (de) 2000-11-30 2002-06-13 Gruenenthal Gmbh Substituierte Amino-furan-2-yl-essigsäure- und Amino-thien-2-yl-essigsäure-Derivate
US7074801B1 (en) 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
IL159538A0 (en) 2001-06-28 2004-06-01 Pliva D D 8/17 heterocyclic compounds and uses thereof as d-alanyl-d-alanine ligase inhibitors
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
EP1578722A4 (en) 2001-10-12 2006-09-06 Irm Llc KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF
DE10202468A1 (de) 2002-01-23 2004-09-30 Faustus Forschungs Cie. Translational Cancer Research Gmbh Pteridinderivate, Verfahren zu deren Herstellung und ihre Verwendung
WO2003097615A1 (en) 2002-05-17 2003-11-27 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
JP2006502236A (ja) 2002-09-18 2006-01-19 ファイザー・プロダクツ・インク 形質転換成長因子(tgf)阻害剤としてのトリアゾール誘導体
EP1549614A4 (en) 2002-10-03 2008-04-16 Targegen Inc VASCULATORY AGENTS AND METHODS FOR THEIR APPLICATION
US20050282814A1 (en) 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
WO2004065392A1 (en) 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
CA2523083C (en) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
ATE376421T1 (de) 2003-08-29 2007-11-15 4 Aza Ip Nv Immunosuppressive wirkungen von pteridinderivativen
GB2405793A (en) 2003-09-12 2005-03-16 4 Aza Bioscience Nv Pteridine derivatives for treating TNF-alpha related disorders
DE602004008304T2 (de) 2003-09-12 2008-05-08 4 Aza Ip Nv Pteridin-derivate zur behandlung von erkrankungen im zusammenhang mit tnf-alpha
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
PT1673092E (pt) 2003-10-17 2007-11-23 4 Aza Ip Nv ''derivados de pteridina substituídos com heterociclos e sua utilização em terapia''
CA2545340A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Fused heterocyclic compounds
JP4630820B2 (ja) 2003-12-30 2011-02-09 ヴァソファーム ゲーエムベーハー 4−アミノ−7,8−ジヒドロプテリジン類、これらを含む医薬組成物、および一酸化窒素レベル上昇によってもたらされる疾病の治療に対するそれらの使用
AU2005207821B2 (en) 2004-01-22 2011-02-10 Eli Lilly And Company Selective estrogen receptor modulators for the treatment of vasomotor symptoms
EP1724268A4 (en) 2004-02-20 2010-04-21 Kirin Pharma Kk COMPOUND HAVING TGF-BETA INHIBITING ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
US20080311076A1 (en) 2004-04-28 2008-12-18 Arrow Therapeutics Limited Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents
ES2605792T3 (es) 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
CN1583747A (zh) 2004-05-26 2005-02-23 中国药科大学 蝶呤类一氧化氮合酶抑制剂
PT1778251E (pt) 2004-07-27 2011-06-29 Gilead Sciences Inc Análogos de fosfonato de compostos inibidores de vih
GB0417905D0 (en) 2004-08-11 2004-09-15 Novartis Ag Organic compounds
WO2006035931A1 (ja) 2004-09-30 2006-04-06 Toshiba Solutions Corporation 情報システムの信頼性評価システム、信頼性評価方法、信頼性評価プログラム
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
KR100915481B1 (ko) * 2004-11-09 2009-09-03 에프. 호프만-라 로슈 아게 아미노퀴나졸린 화합물
DE102004057645A1 (de) 2004-11-29 2006-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057595A1 (de) 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
US20090264415A2 (en) 2004-12-30 2009-10-22 Steven De Jonghe Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
MX2007007901A (es) * 2004-12-30 2007-11-07 4 Aza Ip Nv Pirido-(3,2-d)pirimidinas y composiciones farmaceuticas utiles para tratamiento medico.
GB0428475D0 (en) 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
GB0503506D0 (en) 2005-02-21 2005-03-30 4 Aza Bioscience Nv Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
US20090142345A1 (en) 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
US7418747B1 (en) 2005-06-13 2008-09-02 Myers Jason D Furniture
AU2006261607A1 (en) 2005-06-24 2006-12-28 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis C.
TWI404537B (zh) 2005-08-19 2013-08-11 Array Biopharma Inc 作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯
KR20080085232A (ko) 2006-02-17 2008-09-23 화이자 리미티드 Tlr7 조절제로서 3-데아자퓨린 유도체
WO2007135027A1 (de) 2006-05-24 2007-11-29 Boehringer Ingelheim International Gmbh Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind
WO2007135026A2 (de) 2006-05-24 2007-11-29 Boehringer Ingelheim International Gmbh Substituierte pteridine als therapeutika
US20090318456A1 (en) 2006-07-06 2009-12-24 Gilead Sciences, Inc. Substituted pteridines for the treatment and prevention of viral infections
DE102006033718B4 (de) 2006-07-20 2017-10-19 Siemens Aktiengesellschaft Elektrische Maschine mit schräg verlaufenden Magnetpolgrenzen
US10144736B2 (en) 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
US8338435B2 (en) * 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
WO2008009077A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
US8637531B2 (en) 2006-12-26 2014-01-28 Gilead Sciences, Inc. Pyrido(3,2-d)pyridmidines useful for treating viral infections
US8143394B2 (en) 2006-12-26 2012-03-27 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infections
TW200840584A (en) 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
CA2691444C (en) 2007-06-29 2016-06-14 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
PL2185198T3 (pl) 2007-08-02 2015-06-30 Gilead Biologics Inc Inhibitory LOX i L0XL2 oraz ich zastosowania
EA201200631A1 (ru) 2007-11-16 2012-11-30 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
US8536187B2 (en) 2008-07-03 2013-09-17 Gilead Sciences, Inc. 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections
CN102164902B (zh) 2008-07-08 2014-07-23 因塞特公司 作为吲哚胺2,3-双加氧酶的抑制剂的1,2,5-噁二唑
ES2438496T3 (es) 2008-08-01 2014-01-17 Ventirx Pharmaceuticals, Inc. Formulaciones de agonistas de receptores de tipo toll y su uso
US8652843B2 (en) 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
US20110281908A1 (en) 2008-10-06 2011-11-17 Emory University Aminoquinoline Derived Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use
GB0819593D0 (en) 2008-10-24 2008-12-03 Ucb Pharma Sa Therapeutic agents
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
TWI432436B (zh) 2008-12-09 2014-04-01 Gilead Sciences Inc 類鐸受體的調節劑
ES2598358T3 (es) 2009-02-13 2017-01-27 Ucb Pharma, S.A. Derivados de quinolina como inhibidores de PI3K quinasa
AP3622A (en) 2009-05-13 2016-03-02 Gilead Sciences Inc Antiviral compounds
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
CN102781933B (zh) 2009-08-18 2016-01-20 文蒂雷克斯药品公司 作为toll样受体调节剂的取代的苯并氮杂*
HUE032626T2 (en) 2009-08-18 2017-10-30 Ventirx Pharmaceuticals Inc Toll receptor modulator substituted benzoazepines
ES2644286T3 (es) 2009-10-22 2017-11-28 Gilead Sciences, Inc. Derivados de purina o deazapurina útiles para el tratamiento de (entre otros) infecciones víricas
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
CA2781888C (en) 2009-12-11 2019-06-18 Nono Inc. Agents and methods for treating ischemic and other diseases
CA2789022A1 (en) 2010-02-04 2011-08-11 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
WO2011097607A1 (en) 2010-02-08 2011-08-11 Southern Research Institute Anti-viral treatment and assay to screen for anti-viral agent
FR2959510B1 (fr) 2010-04-28 2013-04-26 Centre Nat Rech Scient Derives de pyrido[3,2-d]pyrimidine, leurs procedes de preparation et leurs utilisations therapeutiques
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
TWI535716B (zh) 2010-05-31 2016-06-01 Ono Pharmaceutical Co Purine ketone derivatives
PE20130525A1 (es) 2010-07-02 2013-05-05 Gilead Sciences Inc Derivados de acido 2 quinolinil acetico como compuestos antivirales frente a vih
MA34397B1 (fr) 2010-07-02 2013-07-03 Gilead Sciences Inc Dérivés d'acide napht-2-ylacétique dans le traitement du sida
KR101881724B1 (ko) 2010-08-27 2018-07-24 길리아드 바이오로직스, 인크. 매트릭스 메탈로프로테이나제 9에 대한 항체
US20120082658A1 (en) 2010-10-01 2012-04-05 Ventirx Pharmaceuticals, Inc. Methods for the Treatment of Allergic Diseases
WO2012045090A2 (en) 2010-10-01 2012-04-05 Ventirx Pharmaceuticals, Inc. Therapeutic use of a tlr agonist and combination therapy
WO2012058601A1 (en) 2010-10-28 2012-05-03 Southern Research Institute Small molecule inhibitors of bacterial motility and a high throughput screening assay for their identification
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
UY33775A (es) 2010-12-10 2012-07-31 Gilead Sciences Inc Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
EP3207930A1 (en) 2011-01-12 2017-08-23 VentiRx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
WO2012097173A2 (en) 2011-01-12 2012-07-19 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
CA2827150C (en) 2011-02-12 2018-09-11 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis b infection
US8664230B2 (en) 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
SI3330257T1 (sl) 2011-04-08 2020-07-31 Janssen Sciences Ireland Unlimited Company Derivati pirimidina za zdravljenje virusnih okužb
CA2833377C (en) 2011-04-21 2019-02-12 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
BR112013029537B1 (pt) 2011-05-18 2020-06-30 Janssen Sciences Ireland Uc derivados de quinazolina, seu uso no tratamento de infecções virais e outras doenças e composição farmacêutica que os compreende
WO2013006738A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
CN103930422A (zh) * 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
WO2013027802A1 (ja) 2011-08-23 2013-02-28 中外製薬株式会社 抗腫瘍活性を有する新規な抗ddr1抗体
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2013060881A1 (en) * 2011-10-27 2013-05-02 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Pyridopyrimidines and their therapeutic use
NZ626750A (en) 2011-11-29 2015-08-28 Ono Pharmaceutical Co Purinone derivative hydrochloride
WO2013090840A1 (en) * 2011-12-15 2013-06-20 Gilead Sciences, Inc. 2 -amino- pyrido [3, 2 -d] pyrimidine derivatives as hcv inhibitors
US9399645B2 (en) 2011-12-20 2016-07-26 Boehringer Ingelheim International Gmbh Inhibitors of HIV replication
KR101939710B1 (ko) 2011-12-21 2019-01-17 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
MX357296B (es) 2012-02-08 2018-07-03 Janssen Sciences Ireland Uc Derivados piperidinopirimidinicos para el tratamiento de infecciones viricas.
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
PE20141558A1 (es) 2012-04-20 2014-11-06 Gilead Sciences Inc Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih
CA2873984A1 (en) 2012-05-23 2013-11-28 Stemergie Biotechnology Sa Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof
CA2875692A1 (en) 2012-06-08 2013-12-12 Selcia Limited Macrocyclic inhibitors of flaviviridae viruses
PL2859009T3 (pl) 2012-06-08 2018-03-30 Gilead Sciences, Inc. Makrocykliczne inhibitory wirusów flaviviridae
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
ES2707885T3 (es) 2012-08-10 2019-04-05 Janssen Sciences Ireland Unlimited Co Alquilpirimidinderivados para el tratamiento de infecciones víricas y otras enfermedades
UA115069C2 (uk) 2012-08-28 2017-09-11 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Конденсовані біциклічні похідні сульфамоїлу та їх застосування як лікарських препаратів для лікування гепатиту b
KR20210081451A (ko) 2012-08-28 2021-07-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
CA2881322A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
US9499549B2 (en) 2012-10-10 2016-11-22 Janssen Sciences Ireland Uc Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases
JP6297055B2 (ja) * 2012-11-16 2018-03-20 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染症の治療のための複素環置換2−アミノ−キナゾリン誘導体
MD4841B1 (ro) 2012-12-21 2023-01-31 Gilead Sciences, Inc. Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
RU2015131006A (ru) 2012-12-27 2017-01-30 Джапан Тобакко Инк. ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ СПИРОПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В МЕДИЦИНЕ В КАЧЕСТВЕ ИНГИБИТОРА ИНТЕГРАЗЫ ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ)
MX369611B (es) 2013-02-01 2019-11-14 Wellstat Therapeutics Corp Compuestos de amina que tienen actividad anti-inflamatoria, antifungica, antiparasitaria y anticancer.
KR102300861B1 (ko) 2013-02-21 2021-09-10 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
WO2014131847A1 (en) 2013-02-28 2014-09-04 Janssen R&D Ireland Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
MX2015015692A (es) 2013-05-17 2016-03-04 Hoffmann La Roche Novedosas heteroarildihidropirimidinas, unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de hepatitis b.
EP3252058B1 (en) 2013-07-12 2021-01-20 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
NO2865735T3 (es) 2013-07-12 2018-07-21
MY179503A (en) 2013-07-30 2020-11-09 Janssen Sciences Ireland Uc Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
EA201692249A1 (ru) * 2014-06-13 2017-05-31 Джилид Сайэнс, Инк. Ингибиторы фосфатидилинозитол-3-киназы
EP3097102B1 (en) 2015-03-04 2017-10-18 Gilead Sciences, Inc. Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
EP3349757A1 (en) 2015-09-15 2018-07-25 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
JP7171444B2 (ja) 2016-07-01 2022-11-15 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー ウイルス感染治療用のジヒドロピラノピリミジン

Also Published As

Publication number Publication date
LT3321265T (lt) 2020-07-27
BR102016004764B1 (pt) 2020-07-14
AU2017202755C1 (en) 2019-01-17
UA123090C2 (uk) 2021-02-17
CA2978188A1 (en) 2016-09-09
PE20180031A1 (es) 2018-01-09
CY1123226T1 (el) 2021-10-29
DOP2017000203A (es) 2017-10-15
KR101756050B1 (ko) 2017-07-07
JP2017203033A (ja) 2017-11-16
WO2016141092A1 (en) 2016-09-09
CN107108615B (zh) 2020-11-20
AU2020286178A1 (en) 2021-01-07
ES2801380T3 (es) 2021-01-11
US20170281627A1 (en) 2017-10-05
EA201791782A1 (ru) 2018-05-31
HK1226062B (zh) 2017-09-22
US20220218709A1 (en) 2022-07-14
TWI705964B (zh) 2020-10-01
TW201639841A (zh) 2016-11-16
CY1120143T1 (el) 2018-12-12
CL2017002225A1 (es) 2018-04-13
US10285990B2 (en) 2019-05-14
CU20170115A7 (es) 2018-03-13
PH12017501590A1 (en) 2018-02-05
JP6820241B2 (ja) 2021-01-27
US20190282576A1 (en) 2019-09-19
CA2978188C (en) 2020-05-12
DK3321265T3 (da) 2020-06-08
EA035093B1 (ru) 2020-04-27
BR102016004764A2 (pt) 2016-09-06
SG11201606876RA (en) 2016-10-28
HK1254205A1 (zh) 2019-07-12
PT3321265T (pt) 2020-07-07
MX2017011307A (es) 2017-10-20
PL3097102T3 (pl) 2018-04-30
JP6182278B2 (ja) 2017-08-16
CN107108615A (zh) 2017-08-29
JP2023083474A (ja) 2023-06-15
CR20170395A (es) 2017-11-07
JP2017509667A (ja) 2017-04-06
AU2018282291A1 (en) 2019-01-17
EP3722297A1 (en) 2020-10-14
SV2017005528A (es) 2018-11-29
ES2656225T3 (es) 2018-02-26
AU2016216673A1 (en) 2016-09-22
HRP20172003T1 (hr) 2018-02-23
AU2016216673B2 (en) 2017-02-02
PT3097102T (pt) 2018-01-22
AU2018282291B2 (en) 2020-09-10
DK3097102T3 (en) 2018-01-22
EP3321265B1 (en) 2020-05-06
IL254164A0 (en) 2017-10-31
IL254164B (en) 2021-05-31
MA39601A (fr) 2016-11-30
AU2017202755A1 (en) 2017-05-18
CN112174960B (zh) 2023-10-10
MX2020012049A (es) 2022-10-03
US20160289229A1 (en) 2016-10-06
MD20170081A2 (ro) 2018-03-31
NZ735176A (en) 2022-04-29
AU2020286178B2 (en) 2022-11-17
CN112174960A (zh) 2021-01-05
HUE038059T2 (hu) 2018-10-29
KR102394917B1 (ko) 2022-05-09
ZA201705958B (en) 2022-10-26
HUE050029T2 (hu) 2020-11-30
RS56787B1 (sr) 2018-04-30
ME02893B (me) 2018-04-20
KR102335970B1 (ko) 2021-12-07
SI3321265T1 (sl) 2020-07-31
KR20210151993A (ko) 2021-12-14
KR20170114273A (ko) 2017-10-13
HRP20201075T1 (hr) 2020-10-30
AU2017202755B2 (en) 2018-09-20
MD3097102T2 (ro) 2018-02-28
KR20160113243A (ko) 2016-09-28
US9670205B2 (en) 2017-06-06
EP3321265A1 (en) 2018-05-16
CO2017009032A2 (es) 2017-11-10
JP7268064B2 (ja) 2023-05-02
EP3097102A1 (en) 2016-11-30
SA517382248B1 (ar) 2022-10-30
LT3097102T (lt) 2018-01-25
PL3321265T3 (pl) 2020-11-16
JP2021046456A (ja) 2021-03-25
ZA201806702B (en) 2022-10-26
MA51081A (fr) 2020-10-14
SI3097102T1 (en) 2018-02-28
EP3097102B1 (en) 2017-10-18
ECSP17058129A (es) 2017-10-31
UY36577A (es) 2016-09-30

Similar Documents

Publication Publication Date Title
CU20180011A7 (es) Composiciones farmacéuticas que comprenden compuestos derivados de diaminopirido (3,2-d) como moduladores de receptor de tipo toll
CL2018003492A1 (es) Hepatitis b agentes antivirales.
CL2018000952A1 (es) Compuestos útiles como inmunomoduladores
CL2017001769A1 (es) Compuestos derivados de nucleosidos, nucleotidos y análogos de los mismos; composición farmacéutica que los comprende; útiles en el tratamiento de la hepatitis c (divisional de la solicitud 1699-2015).
CY1121804T1 (el) Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους
CU20170160A7 (es) Derivadosde fenil-tieno(2,3-d)pirimidina- hidroxi-ésteres, un proceso para su preparación y composiciones farmacéuticas que lo contienen
CR20160241A (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b
CR20150085A (es) Nuevas 6-aminoacido-heteroarildihidropirmidindas para el tratamiento y profilaxis de la infección del virus de la hepatitis b
CU20170162A7 (es) Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen
PH12018500263A1 (en) Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
EA201790963A1 (ru) Противовирусные соединения
EA201790781A2 (ru) Противовирусные соединения
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
BR112016025423A2 (pt) compostos e composições como agonistas de receptores do tipo toll 7
EA201390576A1 (ru) Противовирусные соединения
BR112014026952A2 (pt) derivados de aminopirimidina pirazol como moduladores lrrk2
DOP2017000202A (es) Desacetoxitubulisina h y análogos de esta
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c&#39;] dipyrrol-2-yl
BR112012029647A2 (pt) novos derivados de pirimidinas
EA201592184A1 (ru) 4&#39;-фтор-2&#39;-метилзамещенные нуклеозидные производные
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
GT201300021A (es) Proceso para preparar compuestos antivirales
DOP2014000034A (es) Compuestos de benzofurano para su uso en el tratamiento de infecciones por el virus de hepatitis c (hcv)
AR101255A1 (es) Derivados de isoindolinona
UY38009A (es) Proceso para la preparación de derivados de quinolina